Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + trastuzumab as adjuvant therapy in HER2-positive early or locally advanced breast cancer
ChiCTR2500095597Phase 4Not yet recruiting
- Sponsor
- Henan Provincial People's Hospital
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pyrotinib and trastuzumab in breast cancer (3 arms), sponsored by Henan Provincial People's Hospital. Primary endpoint: Non-invasive recurrence-free survival. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
pyrotinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500095597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095597.